BSE Live
Apr 08, 16:01Prev. Close
104.20
Open Price
109.50
Bid Price (Qty.)
105.45 (100)
Offer Price (Qty.)
109.00 (49)
NSE Live
Apr 08, 15:42Prev. Close
108.97
Open Price
109.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Indo US Bio-Tech (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | |
| Per Share Ratios | ||||
| Basic EPS (Rs.) | 4.17 | 2.18 | 2.52 | |
| Diluted EPS (Rs.) | 4.17 | 2.18 | 2.52 | |
| Cash EPS (Rs.) | 4.10 | 2.93 | 3.29 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 19.49 | 17.66 | 15.46 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 19.49 | 17.66 | 15.46 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 131.48 | 124.53 | 125.60 | |
| PBDIT/Share (Rs.) | 4.65 | 3.48 | 4.28 | |
| PBIT/Share (Rs.) | 3.89 | 2.73 | 3.51 | |
| PBT/Share (Rs.) | 1.71 | 0.92 | 1.78 | |
| Net Profit/Share (Rs.) | 3.33 | 2.18 | 2.52 | |
| Profitability Ratios | ||||
| PBDIT Margin (%) | 3.53 | 2.79 | 3.40 | |
| PBIT Margin (%) | 2.95 | 2.19 | 2.79 | |
| PBT Margin (%) | 1.29 | 0.73 | 1.41 | |
| Net Profit Margin (%) | 2.53 | 1.75 | 2.00 | |
| Return on Networth / Equity (%) | 17.09 | 12.36 | 16.29 | |
| Return on Capital Employed (%) | 14.73 | 12.22 | 15.93 | |
| Return on Assets (%) | 6.46 | 4.28 | 4.77 | |
| Total Debt/Equity (X) | 0.57 | 0.77 | 0.89 | |
| Asset Turnover Ratio (%) | 255.04 | 244.64 | 238.39 | |
| Liquidity Ratios | ||||
| Current Ratio (X) | 1.41 | 1.21 | 1.23 | |
| Quick Ratio (X) | 0.46 | 0.68 | 0.82 | |
| Inventory Turnover Ratio (X) | 4.76 | 7.07 | 8.29 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||
| Enterprise Value (Cr.) | 0.00 | 0.00 | 0.00 | |
| EV/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA (X) | 0.00 | 0.00 | 0.00 | |
| MarketCap/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 0.00 | 0.00 | 0.00 | |
| Price/Net Operating Revenue | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | 0.00 | 0.00 | 0.00 |
22.01.2026
Indo US Bio-Tec Standalone December 2025 Net Sales at Rs 22.80 crore, down 3.25% Y-o-Y
19.11.2025
Indo US Bio-Tec Standalone September 2025 Net Sales at Rs 30.85 crore, up 39.12% Y-o-Y
08.09.2025
Indo US Bio-Tec Standalone June 2025 Net Sales at Rs 30.77 crore, up 24.48% Y-o-Y
27.05.2025
Indo US Bio-Tec Standalone March 2025 Net Sales at Rs 33.38 crore, up 111.75% Y-o-Y
22.01.2026
Indo US Bio-Tec Standalone December 2025 Net Sales at Rs 22.80 crore, down 3.25% Y-o-Y
19.11.2025
Indo US Bio-Tec Standalone September 2025 Net Sales at Rs 30.85 crore, up 39.12% Y-o-Y
08.09.2025
Indo US Bio-Tec Standalone June 2025 Net Sales at Rs 30.77 crore, up 24.48% Y-o-Y
27.05.2025
Indo US Bio-Tec Standalone March 2025 Net Sales at Rs 33.38 crore, up 111.75% Y-o-Y
09.04.2026
08.04.2026
08.04.2026
07.04.2026
12.02.2026
Q3 results impact: Avanti Feeds, Apex Frozen shares rally up to 19% to fresh record highs
11.02.2026
Titan shares rise 3% to new 52-week high as Q3 results impress: Check brokerages' target prices
10.02.2026
Titan Q3 Results: Net profit rises 61% to Rs 1,684 crore on high gold prices, revenue up 43%
10.02.2026
BSE shares jump 6% to fresh record high after strong Q3 results: Brokerages raise target prices
23.01.2026
Matrimony Q3 PAT may dip 21.8% YoY to Rs. 7.8 cr: ICICI Securities
23.01.2026
India Mart Q3 PAT seen up 27.5% YoY to Rs. 154.3 cr: ICICI Securities
23.01.2026
Just Dial Q3 PAT seen up 17% YoY to Rs. 153.6 cr: ICICI Securities
23.01.2026
Nykaa Q3 PAT seen up 105.7% YoY to Rs. 53.7 cr: ICICI Securities